Role of the INK4a locus in tumor suppression and cell mortality

Cell

Volumn 85, Issue 1, 1996, Pages 27-37

  Serrano, Manuel ^a   Lee, Han Woong ^b   Chin, Lynda ^b   Cordon Cardo, Carlos ^c   Beach, David ^a   DePinho, Ronald A ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE LOCUS; MELANOMA; MOUSE; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0029993450     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81079-X     Document Type: Article

References (76)

1. Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C., and Peters, G. (1994). CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9, 71-79.
2. Bradl, M., Klein-Szanto, A., Porter, S., and Mintz, B. (1991). Malignant melanoma in transgenic mice. Proc. Natl. Acad. Sci. USA 88, 164-168.
3. Bruder, J.T., Heidecker, G., and Rapp, R.R. (1992).Serum-, TPA, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev. 6, 545-556.
4. Cairns, P., Polascik, T.J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J.L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K.R., Hedrick, L., Bova, G.S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. (1995). Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet. 11, 210-212.
5. Clarke, A.R., Maandag, E.R., van Roon, M., van der Lugt, N.M.T., van der Valk, M., Hooper, M.L., Berns, A., and te Riele, H. (1992). Requirement for a functional Rb-1 gene in murine development. Nature 359, 328-330.
6. Conzen, S.D., and Cole, C.N. (1995). The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts. Oncogene 11, 2295-2302.
7. Cordon-Cardo, C., and Richon, V.M. (1994). Expression of the retinoblastoma protein is regulated in normal human tissue. Am. J. Pathol. 144, 500-510.
8. de Gruijl, F.R., and van der Leun, J.C. (1991). Development of skin tumors in hairless mice after discontinuation of ultraviolet irradiation. Cancer Res. 51, 979-984.
9. DiGiovanni, J. (1991). Modification of multistage skin carcinogenesis in mice. Prog. Exp. Tumor Res. 33, 192-229.
10. INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21-29.
11. Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., and Beach, D. (1995). CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577.
12. INK4 mutations. N. Engl. J. Med. 333, 970-974.
13. Gonzalez-Zulueta, M., Shibata, A., Ohneseit, P.F., Spruck, C.H. III, Busch, C., Shamaa, M., Elbaz, M., Nichols, P.W., Gonzalgo, M.L., Malmström, P.-U. and Jones, P.A. (1995a). High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J. Natl. Cancer Inst. 87, 1383-1392.
14. Gonzalez-Zulueta, M., Bender, C.M., Yang, A.S., Nguyen, T., Beart, R.W., Van Tornout, J.M., and Jones, P. (1995b). Methylation of the 5′ CpG island of the p 16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531-4535.
15. Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., Prins, D.E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., and Frants, R. (1995). Homozygotes for CDKN2(p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10, 351-353.
16. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8, 2939-2952.
17. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257-261.
18. Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S. and Peters, G. (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867.
19. INK4 or retino-blastoma protein (pRb), or amplification-associated overexpression of cdk4, is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55, 4833-4836.
20. Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.-P., Davidson, N.E., Sidransky, D., and Baylin, S.B. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525-4530.
21. Hirama, T., and Koeffler, H.P. (1995). Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86, 841-854.
22. Holland, E.A., Beaton, S.C., Becker, T.M., Grulet, O.M.C., Peters, B.A., Rizos, H., Kefford, R.F., and Mann, G.J. (1995). Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11, 2289-2294.
23. Hunter, T. (1991). Cooperation between oncogenes. Cell 64, 249-270.
24. Hunter, T., and Pines, J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79, 573-582.
25. Hussussian, C.J., Struewing, J.P., Goldstein, A.M., Higgins, P.A.T., Ally, D.S., Sheahan, M.D., Clark, W.H. Jr., Tucker, M.A., and Dracopoli, N.C. (1994). Germline p16 mutations in familial melanoma. Nature Genet. 8, 15-21.
26. Ioffe, E., Liu, Y., Bhaumik, M., Poirier, F., Factor, S.M., and Stanley, P. (1995). WW6: an embryonic stem cell line with an inert genetic marker that can be traced in chimeras. Proc. Natl. Acad. Sci. USA 92, 7357-7361.
27. Jacks, T., Fazeli, A., Schmitt, E.M., Bronson, R.T., Goodell, M.A., and Weinberg, R. (1992). Effects of an Rb mutation in the mouse. Nature 359, 295-300.
28. Jiang, W., Zhang, Y.-J., Kahn, S.M., Hollstein, M.C., Santella, R.M., Lu, S.-H., Harris, G.G., Montesano, R., and Weinstein, I.B. (1993). Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA 90, 9026-9030.
29. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S. III, Johnson, B.E., and Skolnick, M.H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
30. Koh, J., Enders, G.H., Dynlacht, B.D., and Harlow, E. (1995).Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510.
31. Kraemer, P.M., Ray, F.A., Brothman, A.R., Bartholdi, M.F., and Cram, L.S. (1986). Spontaneous immortalization rate of cultured Chinese hamster cells. J. Natl. Cancer. Inst. 76, 703-709.
32. Kripke, M.L. (1994). Ultraviolet radiation and immunology: something new under the sun. Cancer Res. 54, 6102-6105.
33. Land, H., Parada, L.F., and Weinberg, R.A. (1983).Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602.
34. Lee, E.Y.-H.P., Chang, C.-Y., Hu, N., Wang, Y.-C.J., Lai, C.-C., Herrup, K., Lee, W.-H., and Bradley, A. (1992). Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288-294.
35. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E., and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
36. Lukas, J., Parry, D., Aagaard, L., Mann, D.J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. (1995a). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503-506.
37. Lukas, J., Bartkova, J., Rohde, M., Strauss, M., and Bartek, J. (1995b). Cyclin D1 is dispensable for G1 control in retinoblastoma-gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15, 2600-2611.
38. Maelandsmo, G.M., Berner, J.-M., Flörenes, V.A., Forus, A., Hovig, E., Fodstad, O., and Myklebost, O. (1995). Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas: relationship to amplification and mRNA levels of CDKA and CCND1. Br. J. Cancer 72, 393-398.
39. INK4A transcript. Cancer Res. 55, 2995-2997.
40. Matsushime, H., Roussel, M.F., Ashmun, R.A., and Sherr, C.J. (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701-713.
41. PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71, 323-334.
42. ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA 92, 6289-6293.
43. Meyerson, M., and Harlow, E. (1994). Identification of a G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14, 2077-2086.
44. Morgan, D.O. (1995). Principles of CDK regulation. Nature 374, 131-134.
45. Motokura, T., Bloom, T., Kim, H.G., Jüppner, H., Ruderman, J.V., Kronenberg, H.M., and Arnold, A. (1991). A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512-515.
46. Newbold, R.F., and Overall, R.W. (1983). Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651.
47. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K., and Carson, D.A. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
48. INK4 in human cancer. Proc. Natl. Acad. Sci. USA 91, 11045-11049.
49. Orlow, I., Lacombe, L., Hannon, G.J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V.E., Zhang, Z.-F., Beach, D., and Cordon-Cardo, C. (1995). Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst. 87, 1524-1529.
50. Palmieri, S. (1989). Oncogene requirements for tumorigenicity: cooperative effects between retroviral oncogenes. Curr. Topics Microbiol. Immunol. 148, 43-91.
51. Pollock, P.M., Pearson, J.V., and Hayward, N.K. (1996). Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosom. Cancer 15, 77-88.
52. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. (1995a). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000.
53. INK4b genes. Oncogene 11, 635-645.
54. Röhme, D. (1981). Evidence for a relationship between longevity of mammalian species and life spans of normal fibroblasts in vitro and erythrocytes in vivo. Proc. Natl. Acad. Sci. USA 78, 5009-5013.
55. Ruley, H.E. (1990). Transforming collaborations between ras and nuclear oncogenes. Cancer Cells 2, 258-268.
56. Schmidt, E.E., Ichimura, K., Reifenberger, G., and Collins, V.P. (1994). CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321-6324.
57. Serrano, M., Hannon, G.J., and Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
58. INK4. Science 267, 249-252.
59. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55, 6200-6209.
60. INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505-509.
61. Sherr, C.J., and Roberts, J.M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
62. Silvers, W.K. (1979). The Coat Colors of Mice: A Model for Mammalian Gene Action and Interaction. (New York: Springer-Verlag, Incorporated.)
63. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S.V., Katcher, H., Parry, D., Peters, G., and Kamb, A. (1995a). Complex structure and regulation of the p16 (MTS1) locus. Cancer Res. 55, 2988-2994.
64. Stone, S., Dayananth, P., Jiang, P., Weaver-Feldhaus, J.M., Tavtigian,. S.V., Cannon-Albright, L., and Kamb, A. (1995b). Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 11, 987-991.
65. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene. Cell 65, 1153-1163.
66. Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimlinig, A., and Louis, D.N. (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150-153.
67. INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet. 4, 1845-1852.
68. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
69. Whelan, A.J., Bartsch, D., and Goodfellow, P.J. (1995). A familial syndrome of pancreatic cancer and melanoma in the CDKN2 tumor-suppressor gene. N. Engl. J. Med. 333, 975-977.
70. Williamson, M.P., Elder, P.A., Shaw, M.E., Devlin, J., and Knowles, M.A. (1995). p16(CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet. 4, 1569-1577.
71. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
72. Xiong, Y., Connolly, T., Futcher, B., and Beach, D. (1991). Human D-type cyclin. Cell 65, 691-699.
73. Xiong, Y., Zhang, H., and Beach, D. (1992). D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71, 505-514.
74. Xiong, Y., Zhang, H., and Beach, D. (1993). Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7, 1572-1583.
75. Yoshida, S., Todoroki, T., Ichikawa, Y., Hanai, S., Suzuki, H., Hori, M., Fukao, K., Miwa, M., and Uchida, K. (1995). Mutations of p76Ink4/ CDKN2 and p75Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 55, 2756-2760.
76. INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99.